Biochemistry Department, National Hepatology and Tropical Medicine, Cairo, Egypt.
Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine Banha University, Cairo, Egypt.
Infect Disord Drug Targets. 2020;20(6):840-847. doi: 10.2174/1871526519666191112112903.
BACKGROUND & AIMS: Hepatitis B is a potentially life-threatening liver infection and it is a major global health problem. Over the past decade, numerous studies have reported that patients with CLD, especially HCV-positive and HBV-positive patients, have decreased 25(OH) D levels. The current study was designed to assess the serum levels of vitamin D [25(OH) D3] in chronic hepatitis B patients, before and during treatment with antiviral therapy.
It was a prospective study in which 80 subjects were enrolled between December 2017 and June 2018. A total of 50 treatment-naïve chronic HBV patients and 30 healthy subjects were recruited. The studied cases received treatment in the form of Lamivudine 100 mg tablet, once daily. Full routine laboratory investigations, HBV DNA measurement by real-time PCR were conducted once before initiation of antiviral treatment and again at least 6 months later. Serum vitamin D level [25(OH)D3 was assessed twice, once before initiation of antiviral treatment and again at least 6 months later. This was done for all the patients enrolled in the study.
The studied cases showed a significantly low mean serum Vitamin D level when assessed before treatment (21.6 ± 5.8 ng/ml), compared to the level after 6 ms of treatment (31.1 ± 7.3 ng/ml) which was comparable to that of the control group (33.4 ± 5 ng/ml).
The present study highlights the impact of antiviral therapy on vitamin D deficiency in CHB patients, where effective therapy improves vitamin D levels. Meanwhile, it is recommended to study the impact of vitamin D replacement and correction on the disease progression or regression.
乙型肝炎是一种潜在危及生命的肝脏感染，也是一个全球性的主要健康问题。在过去的十年中，许多研究报告称，患有 CLD 的患者，特别是 HCV 阳性和 HBV 阳性的患者，25（OH）D 水平降低。本研究旨在评估慢性乙型肝炎患者在接受抗病毒治疗前后血清维生素 D [25（OH）D3]水平。
这是一项前瞻性研究，2017 年 12 月至 2018 年 6 月期间共纳入 80 例患者。共纳入 50 例初治慢性 HBV 患者和 30 例健康对照者。研究病例接受拉米夫定 100mg 片剂，每日 1 次治疗。所有入组患者均进行了全常规实验室检查和实时 PCR 检测 HBV DNA。在开始抗病毒治疗前和至少 6 个月后各进行一次。两次评估血清维生素 D 水平[25（OH）D3]，一次在开始抗病毒治疗前，另一次在至少 6 个月后。
研究病例在治疗前（21.6 ± 5.8ng/ml）的平均血清维生素 D 水平显著较低，而治疗 6 个月后（31.1 ± 7.3ng/ml）的水平与对照组（33.4 ± 5ng/ml）相当。
本研究强调了抗病毒治疗对 CHB 患者维生素 D 缺乏的影响，有效的治疗可以改善维生素 D 水平。同时，建议研究维生素 D 替代和纠正对疾病进展或消退的影响。
